Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab

Lorenzo Bertani,Brigida Barberio,Marco Fornili,Luca Antonioli,Federico Zanzi,Cesare Casadei,Laura Benvenuti,Sonia Facchin,Vanessa D'Antongiovanni,Greta Lorenzon,Linda Ceccarelli,Laura Baglietto,Nicola de Bortoli,Massimo Bellini,Francesco Costa,Edoardo Vincenzo Savarino,Matteo Fornai

Digestive and Liver Disease（2022）

引用 4|浏览11

暂无评分

摘要

Our study suggests that serum oncostatin M is a drug-specific biomarker, since it could be used to predict therapeutic effectiveness to anti-TNFs but not to vedolizumab. Moreover, these results emphasize the utility of serum oncostatin M measurement in patients treated with anti-TNF.

查看译文

关键词

Crohn's disease,Ulcerative colitis,Biomarkers,Inflammation,Inflammatory bowel disease,Biologics (IBD)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要